| Name | Title | Contact Details |
|---|
Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralizati.
Apexigen, Inc. is a privately held biopharmaceutical company discovering and developing innovative antibody therapeutics for the treatment of life-threatening and difficult-to-treat diseases. Using its proprietary antibody technology platform, Apexigen has discovered a pipeline of product candidates, which are currently at varying stages of development. The lead product candidate, APX005M, is a novel immuno-oncology antibody that stimulates and enhances an immune response against cancer. Apexigen is developing other product candidates in partnership with four leading biopharmaceutical companies in China. In addition, Apexigen has formed strategic partnerships with multi-national pharmaceutical companies, including Janssen Biotech, Alcon Laboratories and Toray Industries to discover first-in-class antibody lead candidates for the partners' programs.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Rainier is a uniquely diverse manufacturing company, producing a variety of display, shelter, fabric and shading products. Our mission is to create the highest quality available in everything we create--using the best technology and materials. Rainier consistently meets demanding requirements--and we`re at our best creating new solutions.